Use of positron emission tomography in sarcoidosis;Apport de la tomographie par émission de positons dans la prise en charge de la sarcoïdose

Revue de Medecine Interne

Volumn 32, Issue 2, 2011, Pages 101-108

  Bonardel, G ^a   Carmoi, T ^a   Gontier, E ^a   Lecoules, S ^a   Cambon, A ^a   Foehrenbach, H ^a   Algayres, J P ^a  

^a University of Paris Descartes   (France)

Author keywords

Fluorodesoxyglucose (18F FDG); Granulomatosis; Positron emission tomography (PET); Sarcoidosis; Staging; Treatment outcome

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 67;

IMAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; SARCOIDOSIS; SCINTIGRAPHY; SENSITIVITY ANALYSIS; SHORT SURVEY; STAGING; TREATMENT RESPONSE;

FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOIDOSIS;

EID: 78751617196     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2010.07.023     Document Type: Short Survey

References (36)

1. Rohren E.M., Turkington T.G., Coleman R.E. Clinical applications of PET in oncology. Radiology 2004, 231:305-332.
2. Bourguet P. Standards, options et recommandations 2002. Utilisation de la tomographie par émission de positons au [18F]-FDG en cancérologie. Bull Cancer 2003, 90:S1-109. Groupes de travail SOR.
3. Fletcher J.W., Djulbegovic B., Soares H.P., Siegel B.A., Lowe V.J., Lyman G.H., et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008, 49:480-508.
4. Bonardel G., Lecoules S., Mantzarides M., Carmoi T., Gontier E., Blade J.S., et al. Positron emission tomography in internal medicine. Presse Med 2008, 37:460-469.
5. Love C., Tomas M.B., Tronco G.G., Plestro C.J. FDG PET of infection and inflammation. Radiographics 2005, 25:1357-1368.
6. Meller J., Sahlmann C.O., Scheel A.K. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007, 48:35-45.
7. Alavi A., Gupta N., Alberini J.L., Hickeson M., Adam L.E., Bhargava P., et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002, 32:293-321.
8. Alavi A., Buchpiguel C.A., Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?. J Nucl Med 1994, 35:1650-1652.
9. Xiu Y., Yu J.Q., Cheng A., Kumar R., Alavi A., Zhunang H. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med 2005, 30:193-195.
10. Chang J.M., Lee H.J., Goo J.M., Lee H.Y., Lee J.J., Chung J.K., et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 2006, 7:57-69.
11. Nishiyama Y., Yamamoto Y., Fukunaga K., Takinami H., Iwado Y., Satoh K., et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006, 47:1571-1576.
12. Nguyen B.D. F-18 FDG PET imaging of disseminated sarcoidosis. Clin Nucl Med 2007, 32:53-54.
13. Teirstein A.S., Machac J., Almeida O., Lu P., Padilla M.L., Iannuzzi M.C. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007, 132:1949-1953.
14. Braun J.J., Kessler R., Constantinesco A., Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008, 35:1537-1543.
15. Prager E., Wehrschuetz M., Bisail B., Woltsche M., Schwarz T., Lanz H., et al. Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging. Nuklearmedizin 2008, 47:18-23.
16. Krüger S., Buck A.K., Mottaghy F.M., Pauls S., Schelzig H., Hombach V., et al. Use of integrated FDG-PET/CT in sarcoidosis. Clin Imaging 2008, 32:269-273.
17. Okumura W., Iwasaki T., Toyama T., Iso T., Arai M., Oriuchi N., et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004, 45:1289-1298.
18. Ishimaru S., Tsujino I., Takei T., Tsukamoto E., Sakaue S., Kamigaki M., et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005, 26:1538-1543.
19. Ohira H., Tsujino I., Ishimaru S., Oyama N., Takei T., Tsukamoto E., et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008, 35:933-941.
20. Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr Opin Pulm Med 2009, 15:507-512.
21. Dubey N., Miletich R.S., Wasay M., Mechtler L.L., Bakshi R. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 2002, 205:77-81.
22. Aide N., Benayoun M., Kerrou K., Khalil A., Cadranel J., Talbot J.N. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol 2007, 80:67-71.
23. Dufour J.F., Billotey C., Streichenberger N., Bouhour F., Broussolle C., Sève P. Sarcoidosis demonstrated by fluorodeoxyglucose positron emission tomography in a case of granulomatous myopathy. Rev Med Interne 2007, 28:568-570.
24. Pavic M., Debourdeau P., Vacelet V., Rousset H. Sarcoidosis and sarcoid reactions in cancer. Rev Med Interne 2008, 29:39-45.
25. Aide N., Allouache D., Ollivier Y., de Raucourt S., Switsers O., Bardet S. Early 2'-deoxy-2'-[18F]fluoro-D-glucose PET metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like lesions. Mol Imaging Biol 2009, 11:224-228.
26. Avram A.M., Mackie G.C., Schneider B.J., Kalemkerian G.P., Shulkin B.L. Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide. Clin Nucl Med 2006, 31:197-200.
27. Klech H., Kohn H., Kummer F., Mostbeck A. Assessment of activity in sarcoidosis. Sensitivity and specificity of 67Gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations. Chest 1982, 82:732-738.
28. Lawrence E.C., Teague R.B., Gottlieb M.S., Jhingran S.G., Lieberman J. Serial changes in markers of disease activity with corticosteroid treatment in sarcoidosis. Am J Med 1983, 74:747-756.
29. Baughman R.P., Fernandez M., Bosken C.H., Mantil J., Hurtubise P. Comparison of gallium 67 scanning, bronchoalveolar lavage and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis: predicting response to therapy. Am Rev Respir Dis 1984, 129:676-681.
30. Alavi A., Palevsky H.I. Gallium-67-citrate scanning in the assessment of disease activity in sarcoidosis. J Nucl Med 1992, 33:751-755.
31. Keijsers R.G., Verzijlbergen F.J., Oyen W.J., van den Bosch J.M., Ruven H.J., van Velzen-Blad H., et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009, 36:1131-1137.
32. Brudin L.H., Valind S.O., Rhodes C.G., Pantin C.F., Sweatman M., Jones T., et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994, 21:297-305.
33. El-Haddad G., Zhuang H., Gupta N., Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004, 34:313-329.
34. Kaira K., Ishizuka T., Yanagitani N., Sunaga N., Hisada T., Mori M. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med 2007, 32:114-116.
35. Keijsers R.G., Verzijlbergen J.F., van Diepen D.M., van den Bosch J.M., Grutters J.C. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008, 25:143-149.
36. Kaira K., Oriuchi N., Otani Y., Yanagitani N., Sunaga N., Hisada T., et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007, 131:1019-1027.